Cargando…
Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion
Chronic obstructive pulmonary disease (COPD) exacerbations are an important cause of the considerable morbidity and mortality found in COPD. COPD exacerbations increase with increasing severity of COPD, and some patients are prone to frequent exacerbations leading to hospital admission and readmissi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110639/ https://www.ncbi.nlm.nih.gov/pubmed/32288656 http://dx.doi.org/10.1016/j.cair.2006.02.001 |
_version_ | 1783513092677697536 |
---|---|
author | Tesfaigzi, Yohannes Meek, Paula Lareau, Suzanne |
author_facet | Tesfaigzi, Yohannes Meek, Paula Lareau, Suzanne |
author_sort | Tesfaigzi, Yohannes |
collection | PubMed |
description | Chronic obstructive pulmonary disease (COPD) exacerbations are an important cause of the considerable morbidity and mortality found in COPD. COPD exacerbations increase with increasing severity of COPD, and some patients are prone to frequent exacerbations leading to hospital admission and readmission. These frequent exacerbations may have considerable impact on quality of life and activities of daily living. Factors that increase the risk for COPD exacerbations are associated with increased airway inflammation caused by common pollutants and bacterial and/or viral infections. These inflammatory responses cause mucus hypersecretion and, thereby, airway obstruction and associated exacerbations. While chronic mucus hypersecretion is a significant risk factor for frequent and severe exacerbations, patients with chronic mucus hypersecretion have a lower rate of relapse after initial treatment for acute exacerbation. The benefit of antibiotics for treatment of COPD exacerbations is small but significant. While the mechanisms of actions are not clear, mucolytic agents reduce the number of days of disability in subjects with exacerbations. Reducing mucous cell numbers in small airways could be a useful way to reduce chronic mucus hypersecretion. Our studies suggest that programmed cell death is crucial in the resolution of metaplastic mucous cells, and understanding these mechanisms may provide novel therapies to reduce the risk of COPD exacerbations. |
format | Online Article Text |
id | pubmed-7110639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71106392020-04-02 Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion Tesfaigzi, Yohannes Meek, Paula Lareau, Suzanne Clin Appl Immunol Rev Article Chronic obstructive pulmonary disease (COPD) exacerbations are an important cause of the considerable morbidity and mortality found in COPD. COPD exacerbations increase with increasing severity of COPD, and some patients are prone to frequent exacerbations leading to hospital admission and readmission. These frequent exacerbations may have considerable impact on quality of life and activities of daily living. Factors that increase the risk for COPD exacerbations are associated with increased airway inflammation caused by common pollutants and bacterial and/or viral infections. These inflammatory responses cause mucus hypersecretion and, thereby, airway obstruction and associated exacerbations. While chronic mucus hypersecretion is a significant risk factor for frequent and severe exacerbations, patients with chronic mucus hypersecretion have a lower rate of relapse after initial treatment for acute exacerbation. The benefit of antibiotics for treatment of COPD exacerbations is small but significant. While the mechanisms of actions are not clear, mucolytic agents reduce the number of days of disability in subjects with exacerbations. Reducing mucous cell numbers in small airways could be a useful way to reduce chronic mucus hypersecretion. Our studies suggest that programmed cell death is crucial in the resolution of metaplastic mucous cells, and understanding these mechanisms may provide novel therapies to reduce the risk of COPD exacerbations. Elsevier Inc. 2006 2006-06-28 /pmc/articles/PMC7110639/ /pubmed/32288656 http://dx.doi.org/10.1016/j.cair.2006.02.001 Text en Copyright © 2006 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tesfaigzi, Yohannes Meek, Paula Lareau, Suzanne Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion |
title | Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion |
title_full | Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion |
title_fullStr | Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion |
title_full_unstemmed | Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion |
title_short | Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion |
title_sort | exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110639/ https://www.ncbi.nlm.nih.gov/pubmed/32288656 http://dx.doi.org/10.1016/j.cair.2006.02.001 |
work_keys_str_mv | AT tesfaigziyohannes exacerbationsofchronicobstructivepulmonarydiseaseandchronicmucushypersecretion AT meekpaula exacerbationsofchronicobstructivepulmonarydiseaseandchronicmucushypersecretion AT lareausuzanne exacerbationsofchronicobstructivepulmonarydiseaseandchronicmucushypersecretion |